• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (25)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Treatment Adherence  • Review  • Randomized Controlled Trial  • Drug Therapy  • Adherence  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Implications for Assessment of Adverse Effects

Winfried Rief, PhD; Jerry Avorn, MD; Arthur J. Barsky, MD

Arch Intern Med. 2006;166:155-160.

Medication-attributed adverse effects are a frequent reason for poor compliance in practice and in clinical studies and are also common in patients receiving placebo. The occurrence of adverse effects in placebo groups can clarify the assessment of adverse event reporting. We analyzed data from randomized, placebo-controlled trials of statin drugs published since 1992 with sample sizes larger than 100 subjects. Reports of adverse effects and discontinuation rates in placebo groups were evaluated. We compared data on adverse effect profiles in placebo groups between trials and with expected rates from population-based studies. We also sought to determine the range of adverse effect ascertainment methods used in different studies. Methods of ascertainment of adverse events varied widely across studies. Overall, 4% to 26% of patients in the control groups of large trials of statin drugs discontinued placebo use because of perceived adverse effects. The symptom rate in placebo groups varied substantially across trials (up to a ratio of 13:1 for possibly drug-related symptoms, eg, headache, 0.2%-2.7%, or abdominal pain, 0.9%-3.9%) and were often markedly lower than those found in the general population (eg, fatigue, 1.9%-3.4%) in trials of statin drugs vs 17.7% in the general population. In conclusion, the widely varying rates of adverse effects reported by patients taking placebo and the high prevalence of such symptoms in the general population should be considered by both trialists and clinicians. In addition, variability of adverse effect ascertainment is considerable and suggests the need for better standardization in research.

Author Affiliations: Department of Psychiatry (Drs Rief and Barsky) and Division of Pharmacoepidemiology and Pharmacoeconomics (Dr Avorn), Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; and Department of Clinical Psychology, Philipps University, Marburg, Germany (Dr Rief).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Nocebo Effect and Its Relevance for Clinical Practice
Colloca and Miller
Psychosom. Med. 2011;73:598-603.
ABSTRACT | FULL TEXT  

Lessons learned from placebo groups in antidepressant trials
Mora et al.
Phil Trans R Soc B 2011;366:1879-1888.
ABSTRACT | FULL TEXT  

Risk Factors for Self-Reported Adverse Drug Events Among Medicare Enrollees
Oladimeji et al.
The Annals of Pharmacotherapy 2008;42:53-61.
ABSTRACT | FULL TEXT